The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC or CRC tumor tissue.
Oncology

Advance breast cancer biomarker discoveries

Making a difference in breast cancer

Breast cancer is the world's most prevalent female cancer, with 2.3 million women diagnosed in 2022 (1).

It is a complex group of tumors with diverse histology and molecular signatures. Some genomic alterations in breast cancer are clinically actionable with targeted therapies. Understanding these biomarkers, and then developing therapies that target them, is the key to improving diagnosis and treatment.

Discover how we can help take your breast cancer care and clinical research to the next level.

Explore relevant breast cancer targets

Expert webinar

In this on-demand webinar, Dr. Lawrence Weiss, Chief Medical Officer, NeoGenomics, discusses his experience using qPCR in breast cancer.

Watch webinar
Dr. Lawrence Weiss profile image

Using NGS panels in clinical cancer research

Dr. Fergus Couch, Mayo Clinic Cancer Center and the Center for Individualized Medicine, investigates the role of gene mutations in breast and pancreatic cancers using a QIAseq panel.

References

1. World Health Organization WHO). Breast Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Accessed: September 26, 2024.

2. Litton, J.K., Burstein, H.J., Turner, N.C. (2019) Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715.